Market Outlook

The availability of premium-priced branded agents prescribed in doublet, triplet, and quadruplet regimens, particularly Darzalex-based therapies, has had an impressive impact on the multiple myeloma treatment landscape. While BMS’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of multiple myeloma therapy, emerging agents such as GlaxoSmithKline’s (GSK’s) belantamab mafodotin, BMS / Bluebird bio’s ide-cel, Sanofi / ImmunoGen’s isatuximab, and Oncopeptide’s Ygalo are pursuing initial approvals. Immense clinical and commercial potential still remains in multiple myeloma for therapies with improved efficacy and novel mechanisms of action, that can fulfill a need in underserved patient segments such as smoldering multiple myeloma.

Questions Answered

  • What is the size of the drug-treatable multiple myeloma population, and will drug-treatment rates vary over time?
  • How will the use of Revlimid and Velcade change over the forecast period? What impact will generic entries of these pivotal agents have on the multiple myeloma market?
  • What are thought leaders’ opinions on agents such as Sanofi / ImmunoGen’s Sarclisa, BMS / Bluebird Bio’s ide-cel, GSK’s belantamab mafodotin, and Genmab / Janssen’s subcutaneous formulation of Darzalex?
  • What are the drivers and constraints in the multiple myeloma market? How will the entry of new antimyeloma agents shape the multiple myeloma market?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Scope

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating multiple myeloma.

Epidemiology: Incidence of multiple myeloma by country, segmented by symptom.

Emerging therapies: Phase III/PR: 5 drugs; coverage of select Phase I and II products.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
      • Multiple Myeloma - Key Findings
    • Key Updates
      • December 2019
      • March 2020
      • August 2019
      • June 2019
      • December 2018
      • October 2018
      • September 2018
      • May 2018
      • March 2018
    • Market Outlook
      • Key Findings
        • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Multiple Myeloma?
        • What Factors Are Constraining the Market for Multiple Myeloma?
      • Segment-Specific Trends
        • Smoldering Multiple Myeloma
        • First-Line Transplant-Eligible Multiple Myeloma
        • First-Line Transplant-Ineligible Multiple Myeloma
        • Relapsed/Refractory Multiple Myeloma
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
        • Overview
      • Risk Factors
      • Staging and Classification
        • Classification of Multiple Myeloma
        • Staging of Multiple Myeloma
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Diagnosed Incident Cases of Multiple Myeloma by Symptoms
        • Asymptomatic Multiple Myeloma Progression to Symptomatic Multiple Myeloma
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Immunomodulatory Agents
        • Proteasome Inhibitors
        • Histone Deacetylase Inhibitors
        • Cell-Surface-Targeted Agents
        • Selective Inhibitors of Nuclear Export
      • Medical Practice
        • Asymptomatic Multiple Myeloma
        • First-Line Transplant-Eligible Multiple Myeloma
        • First-Line Transplant-Ineligible Multiple Myeloma
        • Relapsed/Refractory Multiple Myeloma
        • Region-Specific Treatment Practices
    • Unmet Need
      • Attainment of Unmet Needs
        • Current and Future Attainment of Unmet Needs in Multiple Myeloma
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Apoptosis-Inducing Agents
        • CAR T-Cell Therapies
        • Antibody-Drug Conjugates
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
        • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Multiple Myeloma Bibliography

Author(s): Snigdha Gupta, Ph.D; Nishant Kumar, MPH

Dr. Snigdha Gupta is a Lead Analyst in the oncology team at Decision Resources Group with expertise in multiple oncology indications including non-small cell lung cancer and multiple myeloma. Prior to joining DRG, Dr. Snigdha Gupta was a subject matter expert in immune-oncology, autoimmunity and dealt in generating in-depth framework based scientific analyses for client projects. In her previous organizations, she was involved in the planning and execution of the IND enabling preclinical studies. She has been instrumental in the stage-up of two small molecules at Bioxcel Therapeutics and Daiichi Sankyo Pharma India Pvt. Ltd. Dr. Gupta holds in infectious diseases from the Indian Institute of Chemical Biology, Jadavpur University, Kolkata while her post-doctoral fellowship is from the Mucosal immunology labs of National Institute of Immunology, New Delhi.

Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.


Related Reports

Multiple Myeloma | Geographic Focus: China | Multiple Myeloma | China In-Depth | China

MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the intro...

View Details

Multiple Myeloma | Disease Landscape and Forecast | G7 | 2019

Market Outlook The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in not just doublet an...

View Details

Multiple Myeloma | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK Successive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapi...

View Details

Multiple Myeloma | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple myeloma patient p...

View Details